phrykt

ADC Therapeutics SA (ADCT): who owns it and who trades it

As of Nov 16, 2026, ADCT insiders reported 6 open-market sales worth $19.6M and no purchases in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was RedCo II Master Fund, L.P. (10% owner), with $19.6M. 3 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Adc Therapeutics Sa

From the latest filings

Overall: about as much buying as selling. Insiders mostly sold. Famous investors mostly bought. Funds was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns ADCT

114 funds and institutions reported ADCT shares worth $99.8M at the end of Q2 2026, about 73% of the company. The largest holder is Nantahala Capital Management, LLC with 19.4%.

Funds and institutions (13F) 73%Everyone else 27%

10 largest owners, by share of the company

Nantahala Capital Management, LLC19.4%
Redmile Group, LLC9.1%
TCG Crossover Management, LLC9.0%
Prosight Management, LP6.2%
BlackRock, Inc.5.5%
Point72 Asset Management, L.P.2.9%
Morgan Stanley2.4%
Millennium Management LLC2.3%
Citadel Advisors LLC1.6%
Goldman Sachs Group Inc1.5%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Nantahala Capital Management, LLC24.65M19.38%$26.4M+340%
Redmile Group, LLC11.53M9.06%$12.3M-25%
TCG Crossover Management, LLC11.39M8.96%$12.2MNo change
Prosight Management, LP7.82M6.15%$8.4M-6%
BlackRock, Inc.7.02M5.52%$7.5M+12%
Point72 Asset Management, L.P.3.65M2.87%$3.9M+8%
Morgan Stanley3.05M2.40%$3.3M-20%
Millennium Management LLC2.90M2.28%$3.1M-7%
Citadel Advisors LLC2.05M1.61%$2.2M+414%
Goldman Sachs Group Inc1.91M1.51%$2M+16%
State Street Corp1.69M1.33%$1.8M+8%
Geode Capital Management, LLC1.45M1.14%$1.5M+20%
Bank of America Corp1.29M1.01%$1.4M-3%
Vanguard Portfolio Management LLC897,0920.71%$960K-13%
Two Sigma Investments, LP773,4140.61%$828K+16%
Blue Owl Capital Holdings LP733,5680.58%$785KNo change
D. E. Shaw & Co., Inc.719,3200.57%$770K+196%
Opaleye Management Inc.700,0000.55%$749K–
AQR Capital Management LLC658,1250.52%$704K+177%
BNP Paribas Financial Markets652,8490.51%$699K-24%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, ADCT insiders reported $0 of open-market purchases and $19.6M of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$19.6M
6 trades, 1 people
Sales under a 10b5-1 plan
0%
Share of sale value
Latest trade
Apr 2, 2026
Filed Apr 2, 2026

Purchases and sales by month

$18.2M$18.2MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Apr 2, 2026RedCo II Master Fund, L.P. +210% ownerSale2.63M$3.28$8.6MForm 4
Apr 2, 2026RedCo II Master Fund, L.P. +210% ownerSale2.53M$3.28$8.3MForm 4
Apr 1, 2026RedCo II Master Fund, L.P. +210% ownerSale162,517$3.80$618KForm 4
Apr 1, 2026RedCo II Master Fund, L.P. +210% ownerSale169,265$3.80$643KForm 4
Mar 31, 2026RedCo II Master Fund, L.P. +210% ownerSale196,229$3.75$736KForm 4
Mar 31, 2026RedCo II Master Fund, L.P. +210% ownerSale188,407$3.75$707KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
RedCo II Master Fund, L.P.10% owner–$19.6MApr 2, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

ADCT short interest

Moderate short interest. 5.0% of ADCT shares are sold short: about 1 share in 20. Over the last 12 reports the number of shares short went up 12%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 6.43M ADCT shares were sold short, 5.0% of the shares outstanding, up 1.4% from the report before. At the average daily volume of 964,848 shares, buying them all back would take about 6.7 trading days (days to cover).

Shares short, % of all shares

5.03%May 15Oct 305.61%

Days to cover

6.7May 15Oct 308.7

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20266.43M5.03%+1%964,8486.7
Oct 15, 20266.34M4.97%-8%2.16M2.9
Sep 30, 20266.90M5.40%+28%1.58M4.4
Sep 15, 20265.39M4.22%-14%1.40M3.9
Aug 31, 20266.29M4.92%+2%2.21M2.8
Aug 14, 20266.18M4.84%+21%979,7676.3
Jul 31, 20265.09M4.00%-8%834,0256.1
Jul 15, 20265.53M4.35%-8%1.38M4.0
Jun 30, 20265.99M4.71%-0%1.76M3.4
Jun 15, 20266.00M4.72%-1%4.78M1.3
May 29, 20266.07M4.77%+6%781,8687.8
May 15, 20265.75M4.52%+5%1.46M4.0

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Adc Therapeutics Sa company events

Adc Therapeutics Sa filed 14 reports on Form 8-K in the last 12 months, 1 of them about an important change (leadership). The latest was on Nov 9, 2026.

  1. Nov 9, 2026ResultsReleased financial results. Filing
  2. Nov 4, 2026AnnouncementThe Company announced updated data from an abstract at ASH for the LOTIS-7 Phase 1b trial of ZYNLONTA in combination with glofitamab in relapsed or refractory large B cell lymphoma. Filing
  3. Oct 13, 2026AgreementADC Therapeutics SA entered into securities purchase agreements for the sale of its equity securities to certain institutional investors in a $86.6 million (assuming the cash exercise of the pre-funded warrants) private placement. Filing
  4. Aug 13, 2026ResultsReleased financial results. Filing
  5. Jul 2, 2026LeadershipThe Board of Directors of ADC Therapeutics SA, with the advice of its independent compensation consultant, approved one-time retention awards to certain of the Company’s employees, including its named executive officers as set forth below: Name Title Cash Incentive Award RSU Award Ameet Mallik… Filing
  6. Jun 24, 2026AnnouncementBelow, ADC Therapeutics SA issued a press release, a copy of which is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference herein. Filing
  7. Jun 3, 2026AnnouncementBelow, ADC Therapeutics SA issued a press release and made available a presentation, copies of which are attached as Exhibit 99.1 and Exhibit 99.2, respectively, to this Current Report on Form 8-K and incorporated by reference herein. Filing
  8. Jun 2, 2026VoteReported shareholder vote results. Filing
  9. May 4, 2026ResultsReleased financial results. Filing
  10. Mar 10, 2026ResultsReleased financial results. Filing
  11. Feb 23, 2026AgreementADC Therapeutics SA entered into an amendment to the Purchase and Sale Agreement, dated August 25, 2021 (the “Original Agreement” and, as amended by the Amendment, the “Amended Agreement”), among the Company and entities managed by HealthCare Royalty Management, LLC. Filing
  12. Jan 12, 2026AnnouncementShared information with investors. Filing
  13. Jan 8, 2026ResultsReleased financial results. Filing
  14. Dec 5, 2025AnnouncementADC Therapeutics SA announced updated data from the ongoing LOTIS-7 Phase 1b open-label clinical trial evaluating the safety and efficacy of ZYNLONTA ® in combination with the bispecific antibody glofitamab (COLUMVI ® ) in patients with relapsed or refractory diffuse large B-cell lymphoma (r/r… Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Adc Therapeutics Sa financials

Famous investors that hold ADCT

3 of the 50 well-known investors we track reported holding ADCT in their latest 13F filing. The largest position is Ken Griffin's, worth $3M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Ken Griffin · Citadel AdvisorsQ3 20262.45M$3M0.0%+19%
Steve Cohen · Point72 Asset ManagementQ3 2026447,786$546K0.0%-88%
Jim Simons · Renaissance TechnologiesQ3 2026384,778$469K0.0%New

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named ADCT in the last 120 days.

FiledHolderFormStake
Nov 13, 2026Prosight Fund, LP13G/A0.0%
Nov 13, 2026Prosight Fund, LP13G/A0.0%
Oct 29, 2026Bain Capital Life Sciences Opportunities IV, L.P.13G10.0%
Oct 29, 2026Bain Capital Life Sciences Opportunities IV, L.P.13G10.0%

Questions about ADC Therapeutics SA (ADCT) stock

Who owns the most ADCT stock?

The largest reported owner of ADC Therapeutics SA (ADCT) is Nantahala Capital Management, LLC, with 19.4% of the company. In total, 114 funds and institutions reported holding ADCT at the end of Q2 2026, together about 73% of the shares. See the largest owners.

Are ADCT insiders buying or selling?

In the last 12 months, ADCT insiders reported no open-market purchases and 6 sales worth $19.6M. The latest trade was on Apr 2, 2026. See every trade.

What is the short interest in ADCT?

As of Oct 30, 2026, 6.43M ADCT shares were sold short, 5.0% of the shares outstanding, up 1.4% from the report before. At the average daily volume of 964,848 shares, buying them all back would take about 6.7 trading days (days to cover). See the history.

Which famous investors hold ADCT?

3 of the 50 well-known investors we track reported ADCT in their latest 13F filing, including Ken Griffin, Steve Cohen, Jim Simons. The largest position is worth $3M. See all holders.

Executive pay

Adc Therapeutics Sa's chief executive was paid a total of $2.5M for the year ended Dec 31, 2025, up 33% from $1.8M the year before. In the last 12 months, Adc Therapeutics Sa's executives and directors bought no stock on the open market and sold none.

Chief executive, total pay$2.5MYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$6MThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$1.4MThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.